AU2020902631A0 - Treatment of cd151 related disorders - Google Patents

Treatment of cd151 related disorders

Info

Publication number
AU2020902631A0
AU2020902631A0 AU2020902631A AU2020902631A AU2020902631A0 AU 2020902631 A0 AU2020902631 A0 AU 2020902631A0 AU 2020902631 A AU2020902631 A AU 2020902631A AU 2020902631 A AU2020902631 A AU 2020902631A AU 2020902631 A0 AU2020902631 A0 AU 2020902631A0
Authority
AU
Australia
Prior art keywords
treatment
related disorders
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020902631A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esfam Biotech Pty Ltd
Original Assignee
Esfam Biotech Pty Ltd
Filing date
Publication date
Application filed by Esfam Biotech Pty Ltd filed Critical Esfam Biotech Pty Ltd
Publication of AU2020902631A0 publication Critical patent/AU2020902631A0/en
Priority to PCT/AU2021/050815 priority Critical patent/WO2022020887A1/en
Pending legal-status Critical Current

Links

AU2020902631A 2020-07-27 2020-07-27 Treatment of cd151 related disorders Pending AU2020902631A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/AU2021/050815 WO2022020887A1 (en) 2020-07-27 2021-07-27 Treatment of cd151 related disorders

Publications (1)

Publication Number Publication Date
AU2020902631A0 true AU2020902631A0 (en) 2020-08-06

Family

ID=

Similar Documents

Publication Publication Date Title
EP4010072A4 (en) Treatment of central nervous system disorders
EP3902524A4 (en) Treatment of skin disorders with compositions comprising an egfr inhibitor
EP3977199A4 (en) Electrically-tunable vision aid for treatment of myopia
EP3955937A4 (en) Compounds and methods for the treatment of ocular disorders
EP3735209A4 (en) Treatment of myopic progression
EP3955926A4 (en) Compounds and methods for the treatment of ocular disorders
EP3927428A4 (en) Methods of treatment of respiratory disorders
EP3911313A4 (en) Thienyl-aniline compounds for treatment of dermal disorders
EP4069847A4 (en) Treatment of lower airways disorders
EP4010075A4 (en) Methods for the treatment of apoc3-related diseases and disorders
EP3883567A4 (en) Naphthyridinone-aniline compounds for treatment of dermal disorders
EP3883552A4 (en) Cyanoaryl-aniline compounds for treatment of dermal disorders
AU2020902631A0 (en) Treatment of cd151 related disorders
EP3990457A4 (en) Compounds for treatment of eye disorders
EP3866795A4 (en) Treatment of neurological diseases
AU2021903178A0 (en) Treatment of VEGFA-Related Disease
AU2019900851A0 (en) Treatment of Inflammatory Disorders
AU2020903576A0 (en) Treatment of VEGFA-Related Disease
EP4037689A4 (en) 18-mc for treatment of substance use disorders
AU2020904693A0 (en) MoBiNurse - Future of Health
AU2021902179A0 (en) Treatment of Glaucoma
AU2020904767A0 (en) Treatment of Glaucoma
GB202007054D0 (en) Treatment of lipid disorders
EP3934694A4 (en) Combination therapy for treatment of brain disorders
AU2021903030A0 (en) Methods of treatment